Drug Database
VI

vincristine sulfate

✓ Approved

Pierre Fabre S.A. · Small Molecule · Small Molecule

What is vincristine sulfate?

vincristine sulfate is a small molecule developed by Pierre Fabre S.A.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyPierre Fabre S.A.
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

vincristine sulfate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

Related Research Articles

PubMedMedicine2026-09-19

Primary breast diffuse large B-cell lymphoma mimicking breast carcinoma: A case report and literature review.

Li Longquan L, Yao Hongxi H, Liu Siyu S, Yin Jieting J et al.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal manifestation of non-Hodgkin lymphoma (NHL) that can closely resemble breast carcinoma clinically and radiologically. This overlap may delay accurate diagnosis and appropriate treatment. We report a case of PB-DLBCL in a postmenopausal woman whose initial multimodal imaging findings were suspicious for breast carcinoma, but whose final diagnosis was established by core needle biopsy with immunohistochemical and molecular evaluation. A 59-year-old postmenopausal woman presented with a painless, palpable mass in the right breast that had been present for approximately 3 weeks. Breast ultrasonography, mammography, magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) demonstrated a suspicious right breast mass with ipsilateral axillary lymphadenopathy, initially raising concern for breast carcinoma. Ultrasound-guided core needle biopsy showed diffuse infiltration by atypical lymphoid cells. Immunohistochemistry confirmed a B-cell phenotype, and fluorescence in situ hybridization (FISH) showed no MYC, BCL2, or BCL6 rearrangements. Bone marrow biopsy showed no evidence of marrow involvement. The final diagnosis was PB-DLBCL, non-germinal center B-cell-like (non-GCB) subtype, Ann Arbor stage IIE. The patient received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy. No breast-directed surgery, consolidative radiotherapy, or central nervous system prophylaxis was administered. At 6 weeks after completion of R-CHOP therapy, PET/CT showed complete metabolic resolution of the right breast lesion, with only a residual punctate calcified focus measuring approximately 0.4 × 0.4 × 0.3 cm. The Deauville score decreased from 5 at baseline to 1 after treatment, meeting Lugano criteria for complete response. No clinically significant treatment-related adverse events were documented. PB-DLBCL can closely mimic breast carcinoma on multimodal imaging. Suspicious breast imaging findings do not exclude lymphoma. Tissue diagnosis with adequate immunophenotypic and molecular evaluation is essential before definitive treatment planning to avoid misdiagnosis and unnecessary surgery.

PubMedBMC medical education2026-09-19

Final-year dental students' self-perceived knowledge and self-reported clinical approaches to vital pulp therapy: a single-institution cross-sectional survey.

Sivas Yılmaz Özlem Ö, Güven Kömürcü Ayşegül A, Dinger Esma E, Ateş Melis Oya MO

Undergraduate dental education should prepare students to understand and apply contemporary vital pulp therapy (VPT) procedures in permanent teeth. However, students' self-perceived knowledge, stated treatment preferences, and self-reported clinical approaches regarding VPT may vary according to their theoretical and clinical training. This study aimed to describe final-year dental students' self-perceived knowledge, recognition of VPT procedures, stated treatment preferences, and self-reported clinical approaches regarding VPT. This single-institution cross-sectional survey was conducted among final-year dental students at a dental faculty in Türkiye in June 2025. Of 100 eligible students, 88 completed a 17-item questionnaire (response rate, 88.0%) addressing self-perceived knowledge, sources of information, treatment preferences, reported clinical approaches, rubber dam isolation, hemostatic agents, and material selection in VPT. Data were summarized descriptively using frequencies and percentages. Most students rated their self-perceived knowledge of VPT as moderate (60.2%), while theoretical courses (42.0%) and clinical practice (36.4%) were the main reported sources of VPT information. Direct pulp capping (94.3%), partial pulpotomy (Cvek; 89.8%), and indirect pulp capping (86.4%) were most frequently identified as vital pulp therapy procedures, whereas total pulpotomy was identified as a vital pulp therapy procedure by 53.4% of students. In mature teeth, direct pulp capping was reported more frequently than partial or total pulpotomy. Treatment preferences varied according to pulp exposure size, with a shift from direct pulp capping for 0-1 mm exposures to partial pulpotomy for 1-2 mm exposures and total pulpotomy or root canal treatment for exposures larger than 2 mm. Only 15.9% of students reported applying rubber dam isolation at the beginning of the treatment, and the combined response option "ferric sulfate or aluminum chloride" was selected most frequently for hemostasis (46.6%). Final-year dental students reported moderate self-perceived knowledge of VPT and recognized several commonly used VPT procedures, but their self-reported approaches varied, particularly regarding pulpotomy procedures, rubber dam timing, hemostatic-agent selection, and simplified pulp-exposure scenarios. These findings should be interpreted as self-reported educational indicators rather than objective evidence of clinical competence or broad curricular inadequacy. Multicenter studies using case-based and performance-based assessments are needed to guide undergraduate VPT teaching.

PubMedEnvironmental science & technology2026-09-18

Isotopic Evidence Reveals the Nonlinear Mitigation Efficacy of Coal-derived Sulfate: Enhanced Role of TMI-Catalyzed Oxidation.

Xu Rongshuang R, Shen Jiahui J, Lin Yu-Chi YC, Yang Yuxiao Y et al.

Despite stringent SO2 emission reductions, particulate sulfate (SO42-) concentrations often exhibit a nonlinear response. To reconcile this discrepancy, this study utilized synchronous sulfur isotope (δ34S) observations of precursor SO2 and product sulfate in Nanjing across a decade (winter 2015 vs 2024). Sulfate reductions are observed to lag behind SO2, declining together with elevated δ34S values in ambient sulfate (5.7 ± 1.1‰ vs 6.2 ± 1.3‰) and significantly in SO2 (1.4 ± 1.2‰ vs 6.5 ± 1.6‰), which indicates a shift in emission structure and sulfate formation chemistry. Unexpectedly, while SO2 source apportionment demonstrates a significant decline in contribution of coal combustion to regional SO2 emissions, coal combustion remains the predominant contributor to secondary sulfate, maintaining a stable relative share. This discrepancy implies enhanced conversion efficiency for coal-emitted SO2. We attribute this to the increased contribution of co-emitted transition metal ion (TMI)-catalyzed oxidation (rising from 35.6% to 59.0%), with kinetic calculations underscoring the dominance of the Mn-surface catalysis pathway. Ultimately, these findings suggest that intensified TMI-catalyzed oxidation sustains high sulfate production from coal-emitted SO2 even under low-SO2 conditions, providing a mechanistic explanation for the nonlinear response. These results also highlight the necessity for synergistic co-control strategies within coal-dependent industries.

PubMedPaediatric drugs2026-09-18

Comment on "Safety and Efficacy of Oral Ferric Maltol and Ferrous Sulfate for Iron Deficiency Anemia in Infants, Children and Adolescents: A Multicenter Randomized Trial".

Kaplan Fatih F

PubMedPaediatric drugs2026-09-18

Authors' Reply to Kaplan Comment on "Safety and Efficacy of Oral Ferric Maltol and Ferrous Sulfate for Iron Deficiency Anemia in Infants, Children and Adolescents: A Multicenter Randomized Trial".

Russell Richard K RK

PubMedMolecular biomedicine2026-09-18

Extracellular signal-regulated kinase 3 forms a nuclear complex with Aly/REF export factor and the splicing factor proline and glutamine rich to exacerbate pathological cardiac remodeling due to pressure overload.

Zhou Wen-Ying WY, Wang Feng F, Wang Shu-Yu SY, Wang Li-Guo LG et al.

Pathological cardiac remodeling is a significant contributor to heart failure and mortality. Studies have demonstrated that extracellular signal regulated kinase 3 (ERK3) in cardiac fibroblasts aggravates pressure overload-evoked pathological cardiac remodeling via mitogen activated protein kinase-activated protein kinase-5 (MK5). However, myocardial ERK3 does not activate MK5, thus the role of myocardial ERK3 remains unclear. Through in vivo and in vitro experiments, we revealed that myocardial ERK3 expression increases under pressure overload and the protein accumulates significantly in the nucleus. Using cardiomyocyte-specific Erk3-deficient mice, neonatal rat cardiomyocytes and adult mouse cardiomyocytes, we found that cardiomyocyte-specific Erk3 deficiency ameliorated pressure overload-induced pathological cardiac remodeling in vivo. Co-immunoprecipitation, mass spectrometry, and single nucleus RNA sequencing were used to analyse for the nuclear translocation and downstream signaling mechanisms of ERK3. Specifically, pressure overload enhances the binding of Aly/REF export factor (ALY) to ERK3, resulting in the truncation of the ERK3 C-terminal and its subsequent nuclear translocation to activate the thioredoxin-interacting protein (TXNIP)/NOD-like receptor thermal protein domain associated protein 3 (NLRP3) pathway through the expression of the splicing factor proline and glutamine rich (SFPQ). To screen for targeted drugs, we conducted a virtual screening and identified estrone sulfate as an inhibitor of ALY to counteract hypertrophic effects. Collectively, our findings indicate that estrone sulfate functions as a novel inhibitor of the ALY-ERK3 signaling pathway, potentially serving as a promising therapeutic candidate for the management of pathological cardiac remodeling.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about vincristine sulfate